Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis.

Alisson Pugliesi, Amanda Borges de Oliveira, Ana Beatrice Oliveira,Ricardo Xavier,Licia Maria Henrique da Mota,Manoel Barros Bertolo,Miguel Angel Gonzalez-Gay, Gustavo Citera,Luiz Sergio Fernandes de Carvalho

SBR 2021 Congresso Brasileiro de Reumatologia（2023）

引用 0|浏览4

暂无评分

摘要

We found high heterogeneity among studies comparing rituximab, abatacept, and tocilizumab. On multivariate metaregressions, if the conditions of the RCTs were similar, we estimate that abatacept could increase the chance of reaching an ACR70 response by 2.2-fold compared to tocilizumab.

查看译文

关键词

Rheumatoid arthritis, Rituximab, Abatacept, Tocilizumab, bDMARD, American college of rheumatology, Network meta-analysis, Meta-regression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要